ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Mar. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Cash and Cash Equivalents

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows.

(in thousands)	March 31, 2022		December 31, 2021
Cash and cash equivalents	$	39,769	$	46,156
Restricted cash	1,501		1,501
Total cash, cash equivalents and restricted cash shown in the statements of cash flows	$	41,270	$	47,657

Cash, Cash Equivalents and Restricted Cash, Reconciliation

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows.

(in thousands)	March 31, 2022		December 31, 2021
Cash and cash equivalents	$	39,769	$	46,156
Restricted cash	1,501		1,501
Total cash, cash equivalents and restricted cash shown in the statements of cash flows	$	41,270	$	47,657

Accrued Expenses and Other Current Liabilities

Accrued expenses and other liabilities consist of the following:

(in thousands)	March 31, 2022		December 31, 2021
Accrued payroll	$	166	$	320
Accrued patient treatment costs	1,393		2,086
Accrued clinical research costs	663		479
Accrued manufacturing costs	388		328
Accrued professional services	417		305
Accrued other	320		331
Total accrued expenses and other current liabilities	$	3,347	$	3,849

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following outstanding shares of common stock equivalents were excluded from the computations of diluted loss per share of common stock attributable to common stockholders for the periods presented as the effect of including such securities would be anti-dilutive.

	March 31, 2022	March 31, 2021
Anti-dilutive common stock equivalents:	Number of Shares
Redeemable convertible series 1 preferred stock	4,520,000	4,520,000
Warrants to purchase common stock	5,750,000	11,616,080
Private placement option	—	9,675,000
Options to purchase common stock	2,064,537	1,400,470
Unvested shares of restricted stock units	10,500	262,010
Total anti-dilutive common stock equivalents	12,345,037	27,473,560